ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 82 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $366,000 | -97.0% | 167,208 | -72.8% | 0.01% | -95.5% |
| Q2 2018 | $12,254,000 | -17.9% | 613,635 | -28.0% | 0.11% | -11.3% |
| Q1 2018 | $14,923,000 | -9.4% | 851,774 | +27.5% | 0.12% | -5.3% |
| Q4 2017 | $16,470,000 | +36.4% | 667,884 | +42.7% | 0.13% | +45.6% |
| Q3 2017 | $12,076,000 | +76.2% | 467,884 | +85.2% | 0.09% | +57.9% |
| Q2 2017 | $6,853,000 | +19.1% | 252,683 | +31.0% | 0.06% | +21.3% |
| Q1 2017 | $5,754,000 | +116.6% | 192,957 | +97.2% | 0.05% | +113.6% |
| Q4 2016 | $2,656,000 | – | 97,854 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |